Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Stem Cell Reinfusion in High Grade Gliomas
NCT02976441Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2017
- Primary completion
- Feb 2018
- Modality
- Stem Cell Therapies, Device-based Delivery
01
Overview
Phase 1, open-label, single-arm trial of Stem Cell Educator Therapy in high-grade glioma (HGG), sponsored by Washington University School of Medicine. Primary endpoint: Efficacy of lymphocyte stem cell harvesting and reinfusion at 15 months. Planned start Jan 2017; status: withdrawn.
02
Drugs
Stem Cell Educator Therapy
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02976441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976441.